Laboratorios Farmaceuticos ROVI

Laboratorios Farmaceuticos ROVI EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Laboratorios Farmaceuticos ROVI (ROVI.MC) as of Oct 30, 2026 is 22.26. In the previous year, EV/EBIT (Enterprise Value to EBIT) was 21.69 — a change of 2.65% (higher).

EV/EBIT

22.26

YoY

2.65%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Laboratorios Farmaceuticos ROVI is 2025 22.26 . EV/EBIT (Enterprise Value to EBIT) of Laboratorios Farmaceuticos ROVI was 2024 21.69 . It decreases by 2.65% higher compared to the previous year.

The Laboratorios Farmaceuticos ROVI EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2019
90.88 EUR
Jan 1, 2020
52.14 EUR
Jan 1, 2021
21.24 EUR
Jan 1, 2022
15.22 EUR
Jan 1, 2023
17.68 EUR
Jan 1, 2024
21.69 EUR
Jan 1, 2025
22.26 EUR
Jan 1, 2026 (e)
17.94 EUR
The Laboratorios Farmaceuticos ROVI EV/EBIT history
YEAREV/EBITYoY
est17.94-19.42%
22.26+2.65%
21.69+22.67%
17.68+16.16%
15.22-28.34%
21.24-59.27%
52.14-42.63%
90.88-59.25%
223.03+8.88%
204.84+48.88%
137.59-22.82%
178.27+26.78%
140.61+618.86%
19.56+58.64%
12.33-3.67%
12.80+38.68%
9.23-66.85%
27.84+170.03%
10.31-64.63%
29.15—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Laboratorios Farmaceuticos ROVI Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Laboratorios Farmaceuticos ROVI's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Laboratorios Farmaceuticos ROVI's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Laboratorios Farmaceuticos ROVI's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Laboratorios Farmaceuticos ROVI grows earnings faster than its peers.

Laboratorios Farmaceuticos ROVI Stock analysis

What does Laboratorios Farmaceuticos ROVI do? Laboratorios Farmaceuticos ROVI SA is a Spanish pharmaceutical company that was founded in 1946 by Salvador and Ignacio Ruiz-Salmones. The company is headquartered in Madrid and employs over 1,000 employees. ROVI manufactures a variety of pharmaceutical products and offers services in various areas. The company specializes in the development and manufacturing of specialty preparations in the fields of oncology, hematology, endocrinology, and gastroenterology. The company operates in three business areas: specialty pharmaceuticals, contrast agents, and active ingredients for the industry. The specialty pharmaceuticals business area includes medications for various applications, such as the treatment of cancer, blood disorders, endocrine disorders, gastroenterological disorders, and central nervous system disorders. The contrast agents division produces products for radiology and diagnostics. The products are used in various medical fields, from cardiology to gastroenterology. In the active ingredients for the industry business area, ROVI manufactures active ingredients for other pharmaceutical companies. ROVI specializes in the production of specialty products and relies on collaborations with other companies. The company has strategic partnerships with many companies such as GlaxoSmithKline, Pfizer, Sanofi-Aventis, and Zeltia. This also includes some research collaborations to develop and market products together. The company is also dedicated to the development of biosimilars, which allow for the offering of biologic drugs at a lower price. Biosimilars are copies of biopharmaceuticals that are usually very expensive due to the complex manufacturing process and high development costs. ROVI is also a major producer of vaccines that are distributed worldwide. ROVI has followed a solid growth trajectory in recent years. The company has been able to consistently increase its revenue and profit and is now a major player in the pharmaceutical industry. The company also operates a strong research and development department that constantly develops new products and technologies to improve patient care. In summary, Laboratorios Farmaceuticos ROVI SA is a leading pharmaceutical company specializing in the manufacturing of specialty products. With its subsidiaries in Europe and the USA, ROVI has an international presence and has made a name for itself through its expertise in the development and manufacturing of innovative pharmaceutical products. Laboratorios Farmaceuticos ROVI is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Laboratorios Farmaceuticos ROVI stock

EV/EBIT (Enterprise Value to EBIT) of Laboratorios Farmaceuticos ROVI is 22.26 in 2025.

EV/EBIT (Enterprise Value to EBIT) of Laboratorios Farmaceuticos ROVI changed from 21.69 to 22.26, representing a 2.65% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Laboratorios Farmaceuticos ROVI since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Laboratorios Farmaceuticos ROVI with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Laboratorios Farmaceuticos ROVI

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Laboratorios Farmaceuticos ROVI